Core Viewpoint - Recently, Zhejiang Shuwen Biotechnology Co., Ltd. announced the completion of nearly 100 million C1 round financing and simultaneously initiated C2 round financing, with funds primarily allocated for the promotion of its globally innovative diagnostic products and new product development in the field of women's health [1] Company Overview - Founded in 2011, Shuwen Biotechnology is headquartered in Deqing, Zhejiang, and focuses on the development, production, sales, and medical testing services of in vitro diagnostic reagents for women's health. The company has established R&D, production, and sales bases in multiple locations, including Hangzhou, Jinhua, Xuancheng, and Berlin, Germany, and is recognized as a national high-tech enterprise [2] - The company has formed long-term partnerships with renowned institutions such as Yale University, the University of Chicago, and BioNTech, accumulating over 100 exclusive diagnostic patents and developing several globally innovative diagnostic products [2] Product and Technology Introduction - Shuwen Biotechnology's product line focuses on two core areas of women's health: maternal and infant medicine and precision diagnosis of breast cancer. The company has launched the world's first home self-test product for pregnant women with preeclampsia, CercaTest RED®, and a urine rapid test product, Wenxian'an®, which significantly improves early detection efficiency of the disease [3] - In breast cancer diagnosis, the company has developed over ten detection products covering the entire disease course, including MammaTyper®, which has been included in Spain's breast cancer treatment guidelines and is used for national-level precision diagnosis in Burkina Faso. The products have received CE certification and are sold in nearly fifty countries globally [4] Financing History - C1 Round Financing (2025): Nearly 100 million, led by Jinchuang Investment, with funds used for global market promotion and new product development [6] - B Round Financing (2021): Nearly 100 million, led by Guolian Investment, aimed at developing innovative products in tumor screening and maternal and reproductive health [6] - A+ Round Financing (2018): Tens of millions of RMB, with investment from Boyi Fund [6] - A Round Financing (2017): Investment from Qianhai Mother Fund [6] - Pre-A Round Financing (2016): Investment from Yuansheng Venture Capital [6] - Angel Round Financing (2016): Investments from Zhonghao Capital, Qianhai Mother Fund, and Yuansheng Venture Capital [6]